Imiquimod + Zalifrelimab - UroGen Pharma
Alternative Names: UGN-201 + UGN-301; UGN-302Latest Information Update: 28 May 2024
At a glance
- Originator UroGen Pharma
- Developer Agenus; UroGen Pharma
- Class Aminoquinolines; Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Small molecules
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunostimulants; T lymphocyte stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Intravesicular)
- 31 Jul 2022 UroGen Pharma concludes the collaboration with MD Anderson for non clinical development of imiquimod + zalifrelimab as the research objectives achieved before July 2022
- 18 Mar 2021 UroGen and the University of Texas MD Anderson Cancer Center plans non-clinical studies for imiquimod + zalifrelimab in the first half of 2021